

ASX Announcement | 31 May 2019
Althea Group Holdings (ASX:AGH)

Althea Launches UK Concierge Platform and Commences First Assessments of Patients in the UK

Investment Highlights:

- *Althea Concierge* UK launches successfully with doctors already commencing their first assessments of patients for Althea medical cannabis products
- Althea Concierge UK streamlines the prescription process and facilitates patient referrals from primary care doctors to Althea UK specialist prescribers
- Althea and Drug Science joint educational meetings to be held in June are oversubscribed, with nearly 300 healthcare professionals registered to attend
- Althea sponsored and participated in the recent IOTOD conference in Germany


Friday 31 May 2019: **Australian medicinal cannabis company Althea Group Holdings Limited (ASX:AGH)** through its wholly-owned subsidiary Althea MMJ UK Ltd ('Althea' or 'the Company'), is pleased to announce the launch of *Althea Concierge* UK and the progression of its partnerships with Drug Science and the Improving Outcomes in the Treatment of Opioid Dependence (**IOTOD**) scientific committees.

Althea Concierge UK launches

The *Althea Concierge* medical education platform, which was launched in Australia in September 2018, provides medical education and clinical evidence for healthcare professionals looking to prescribe medicinal cannabis.

The platform supports Althea UK's entry to the market by streamlining the prescription process and facilitating patient referrals from primary care doctors to Althea UK specialist prescribers. The strategy is being leveraged from Althea's successful Australian operations, which has seen significant and sustained increases in patient numbers that are rapidly approaching the 1,000 patient milestone.

Althea Concierge UK is now live at: <https://concierge.althea.co.uk>



The screenshot shows the Althea Concierge UK website interface. On the left is a dark blue sidebar with the Althea logo, the word 'CONCIERGE', and the phone number '0203 983 0888'. Below this is a description: 'A platform for patients, doctors and pharmacists to manage their medicinal cannabis needs in the United Kingdom.' Underneath is a 'Login' section with fields for 'Email Address' (example: john@althea.com) and 'Password', a 'Forgot Password?' link, and a 'Login' button. On the right is a white registration page with a 'BACK TO ALTHEALIFE' link at the top. The page is titled 'Register' and offers three options: 'Patient' (with a medical bag icon), 'Healthcare Professional' (with a person icon), and 'Pharmacist' (with a mortar and pestle icon). Each option includes a brief description of what the user can access and a 'Register' button with a right-pointing arrow.

Partnership with Drug Science Progresses

In further support of Althea's UK expansion, the Company recently announced a partnership with Drug Science, the UK's only completely independent scientific committee on drugs.

Althea has provided Drug Science with an educational grant which will allow the non-profit to use Althea's recently launched *Medical Education In Cannabinoids* learning portal (**MEDIC**) to educate healthcare professionals about medicinal cannabis.

Althea and Drug Science's joint medical education meetings in London and Birmingham have attracted 200 and 69 registrations respectively, just five days after being publicised.

The meetings will be held in London on June 11th and Birmingham on June 12th and will include presentations from Drug Science founder Professor David Nutt, and Canadian prescribers with international credibility.

Sponsored and participated in IOTOD conference

In response to the significant educational gap in the UK, Althea is successfully collaborating with the IOTOD scientific committee.

Through an independent grant to the IOTOD scientific committee, Althea facilitated the training of 265 European healthcare professionals at the IOTOD 2019 annual educational meeting in Frankfurt this month.

The IOTOD conference is an annual, Continuing Medical Education-accredited, two-day event developed in partnership with internationally renowned and leading opioid dependency experts. The conference attracts a multitude of specialists from across the globe and provided Althea with the opportunity to gain increased exposure in Europe due to its location and European focus.

Althea supported the event with a satellite session on medicinal cannabis hosted by Dr Sana-Ara Ahmed, a practising Anaesthesiologist, Interventional Pain and Cannabinoid Medicine Specialist based in Canada.

Althea was the only medicinal cannabis company to participate in the conference and sponsored the event alongside global pharmaceutical companies Camurus (STO:CAMX), Gilead Sciences (NASDAQ:GILD), and AbbVie (NYSE:ABBV).

Working in collaboration, Althea and IOTOD plan to reach over 1,000 more prescribers in the UK in coming months.

Althea Chief Medical Officer Dr Robert Pawinski, said: "We are pleased to have commenced our first assessments of patients in the UK for Althea medical cannabis products. In response to the significant educational gap in the UK, Althea is successfully collaborating with IOTOD, exposing over 280 health professionals to the MEDIC platform, and directly training over 70 prescribers who were interested in medical cannabis in one session. We have multiple seminars, webinars, and small group teachings planned for the months ahead to support the continued expansion of Althea UK, including the already oversubscribed Althea and Drug Science joint educational meetings to be held in June."

Althea CEO & Managing Director Josh Fegan, said: “The launch of *Althea Concierge* UK and progression of our partnerships with two leading UK scientific committees are key developments for our UK expansion. While *Althea Concierge* UK streamlines prescribing pathways for doctors, the partnerships with Drug Science and IOTOD are furthering our educational outreach efforts. Althea is a global medicinal cannabis company and our strategy reflects that. We look forward to continued growth and replicating our highly successful Australian-born strategy abroad, working closely with doctors to provide patients the opportunity to choose an Althea life.”

Website redesign complete

The Company’s redesigned website provides users with quick and easy access to essential information about Althea and includes a refreshed user interface, visual style, and menu system. The website also has a comprehensive investor section and links to *Althea Concierge* and further information about medicinal cannabis. The new website went live this month and is located at the following address: www.althea.life

Ends

For further information, please contact:

Althea

Josh Fegan
CEO & Managing Director
M: 1300 70 20 20
E: contact@althea.life

Media Enquiries

Julia Maguire
The Capital Network
M: +61 419 815 386
E: julia@thecapitalnetwork.com.au

Australian Investors

PAC Partners Securities
M: 03 8633 9834
E: enquiries@pacpartners.com.au

Althea Group Holdings Limited (ASX:AGH)

Althea is an Australian licensed producer, supplier and exporter of pharmaceutical grade medicinal cannabis and is listed publicly on the Australian Securities Exchange (ASX:AGH). Althea also offers a range of education, access and management services to support eligible patients and healthcare professionals in navigating medicinal cannabis treatment pathways.

Althea currently operates within highly regulated medicinal cannabis markets including Australia and the United Kingdom, with plans to expand into emerging markets throughout Asia and Europe.

To learn more, please visit: www.althea.life

Drug Science

Founded in 2010 by Professor David Nutt, Drug Science is the only completely independent, science-led drugs charity, uniquely bringing together leading drugs experts from a wide range of specialisms to carry out groundbreaking original research into drug harms and effects.

Its highly cited papers on all aspects of drug effects and harms attract global coverage and considerable public interest. Drug Science reduces the harms of drugs to the public through providing objective information on drug effects, harms and potential medical uses to the public, professionals and decision makers.

To learn more, please visit: www.drugscience.org.uk

IOTOD

Improving Outcomes in the Treatment of Opioid Dependence is an educational initiative that aims to improve opioid dependence healthcare through a variety of programs, such as the annual conference, the THN toolkit, reports and other online resources.

To learn more, please visit: www.iotodeducation.com